Researchers at Texas A&M University have demonstrated that a nasal spray delivering extracellular vesicles can reverse brain inflammation and restore memory function in aged mice, with effects appearing within weeks and lasting for months.
The therapy targets neuroinflammaging, a chronic inflammatory process in the aging brain linked to cognitive decline and Alzheimer’s disease. By using tiny biological carriers called extracellular vesicles loaded with regulatory microRNAs, the spray bypasses the blood-brain barrier to deliver genetic material directly to brain tissue.
Once absorbed by immune cells in the brain, the vesicles suppress harmful inflammatory pathways including the NLRP3 inflammasome and cGAS–STING system. Simultaneously, they reactivate mitochondria — the cellular power plants — improving energy supply to neurons and enhancing their ability to process and store information.
In preclinical tests, two doses of the spray led to measurable improvements in memory and recognition tasks, with benefits observed equally in male and female subjects — a notable outcome given historical inconsistencies in sex-based responses in biomedical research.
The effects were not transient; cognitive improvements and reduced inflammation persisted for months after treatment, suggesting a sustained reprogramming of brain resilience rather than a temporary symptom fix.
Dr. Ashok Shetty, lead researcher and university distinguished professor at the Institute for Regenerative Medicine, emphasized that the approach aims not just to extend lifespan but to redefine healthy brain aging — keeping individuals mentally sharp, socially engaged, and functionally independent.
He noted the potential societal impact, citing projections that recent dementia cases in the U.S. Could rise from 514,000 in 2020 to 1 million by 2060, underscoring the urgency for scalable, low-risk interventions.
While the results are promising, researchers caution that the findings are based on mouse models and extensive human trials will be needed before clinical application. Scaling the therapy will require significant investment and interdisciplinary collaboration.
Still, the team envisions a future where a simple, two-dose nasal spray could supplant invasive procedures or long-term medication regimens for cognitive disorders, offering a more accessible path to preserving brain health across populations.
How soon could this therapy be available to humans?
Researchers stress that while results in mice are encouraging, human trials are still years away and will require additional funding, safety testing, and regulatory approval before any clinical leverage can be considered.
Why is the equal effectiveness in males and females significant?
Many neurodegenerative treatments display divergent outcomes by sex, but this therapy demonstrated consistent benefits across both genders in preclinical models — a rarity that suggests broader potential applicability in diverse populations.
